HomeCompareMORF vs O

MORF vs O: Dividend Comparison 2026

MORF yields 3.51% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $9.1K in total portfolio value· pulled ahead in Year 6
10 years
MORF
MORF
● Live price
3.51%
Share price
$56.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$439.80
Full MORF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — MORF vs O

📍 O pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMORFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MORF + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MORF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MORF
Annual income on $10K today (after 15% tax)
$298.30/yr
After 10yr DRIP, annual income (after tax)
$373.83/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $3,963.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MORF + O for your $10,000?

MORF: 50%O: 50%
100% O50/50100% MORF
Portfolio after 10yr
$29.7K
Annual income
$2,771.27/yr
Blended yield
9.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

MORF
No analyst data
Price Target
$57.00
+0.0% upside vs current
Range: $57.00 — $57.00
Altman Z
60.9
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MORF buys
0
O buys
0
No recent congressional trades found for MORF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMORFO
Forward yield3.51%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$25.1K$34.2K
Annual income after 10y$439.80$5,102.74
Total dividends collected$4.0K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst price target$57.00$64.00

Year-by-year: MORF vs O ($10,000, DRIP)

YearMORF PortfolioMORF Income/yrO PortfolioO Income/yrGap
1$11,051$350.94$10,818$608.16+$233.00MORF
2$12,187$362.45$11,787$741.68+$400.00MORF
3$13,414$373.56$12,946$911.00+$468.00MORF
4$14,737$384.26$14,345$1,127.94+$392.00MORF
5$16,163$394.55$16,056$1,409.05+$107.00MORF
6← crossover$17,699$404.42$18,171$1,777.83$472.00O
7$19,352$413.88$20,820$2,268.21$1.5KO
8$21,129$422.92$24,188$2,929.90$3.1KO
9$23,040$431.56$28,533$3,837.11$5.5KO
10$25,092$439.80$34,235$5,102.74$9.1KO

MORF vs O: Complete Analysis 2026

MORFStock

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Full MORF Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this MORF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MORF vs SCHDMORF vs JEPIMORF vs KOMORF vs MAINMORF vs STAGMORF vs ADCMORF vs NNNMORF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.